Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC

The VEGFR/EGFR inhibitor anlotinib prolonged PFS and OS in Chinese patients with NSCLC, but additional studies are needed to determine its benefit in other populations.

from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2QULnh5